Sorafenib and entecavir:The dioscuri of treatment for advanced hepatocellular carcinoma?

• 作 者: Salvatore D'Angelo Mario Secondulfo Raffaele De Cristofano Paolo Sorrentino
• 机 构: Liver Unit,Clinical and Experimental Hepatology,S.G.Moscati Hospital,Contrada Amoretta,83100 Avellin
• 出 处: World Journal of Gastroenterology
• 发表日期: 2013年14期
• 关键词: inhibiting proven DNA elongation frontier replication cirrhosis potent steps fet

Hepatitis B virus(HBV) is responsible for 50%-80% of cases of hepatocellular carcinoma(HCC) worldwide.Entecavir(ET) is a potent inhibitor of chronic HBV-DNA polymerase,inhibiting both the priming and elongation steps of viral DNA replication.Sorafenib(SO) has proven efficacy in prolonging survival in patients with advanced HCC.In this frontier report we discuss a possible way to optimize treatment outcomes in patients with HBV and HCC by treatment with ET and SO,on the basis of our practice and published evidence from the literature.

Entecavir (ET) is a potent inhibitor of chronic HBV-DNA polymerase, both of which priming and elongation steps of viral DNA replication (HBV) is responsible for 50% -80% of cases of hepatocellular carcinoma Sorafenib (SO) has proven efficacy in prolonging survival in patients with advanced HCC. This frontier report we discuss a possible way to optimize treatment outcomes in patients with HBV and HCC by treatment with ET and SO, on the basis of our practice and published evidence from the literature.